Amy Conrad

Amy N. Conrad

Experienced Wall Street-facing leader with a passion for growing biotechnology companies through IPO and beyond. Over the last decade, Ms. Conrad has been responsible for creating significant value for multiple biotechnology companies (Anadys, acquired by Roche in late 2011 and Regulus Therapeutics, IPO in Oct. 2012) through strategic investor relations, corporate communications and media planning, fostering deep relationships with market-moving analysts, key bankers and institutional investors, and playing a key role in raising over $225M in capital. Ms. Conrad has expanded her capabilities with the founding of Juniper Point, Inc., a start-up company with headquarters in San Diego, focused on creating value for biotech companies from the inside out.